Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA1 | P02708 | 2/20 | 0.54 |
| ▸ | CHRNG | P07510 | 2/20 | 0.54 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.54 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.54 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.54 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.54 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.54 |
| ▸ | CHRND | Q07001 | 2/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.36 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2292750 | 1.00 | CHRNA1 (0.54) | CHRNA1CHRNGCHRNB1CHRNB2SLC6A2 | |
| SCHEMBL2288623 | 0.86 | CHRNA1 (0.40) | CHRNA1CHRNGCHRNB1CHRNB2SLC6A2 | |
| SCHEMBL2291374 | 0.86 | MAPT (0.40) | CHRNA1CHRNGCHRNB1CHRNB2SLC6A2 | |
| SCHEMBL2288627 | 0.86 | CHRNA1 (0.40) | CHRNA1CHRNGCHRNB1CHRNB2SLC6A2 | |
| SCHEMBL2291371 | 0.86 | MAPT (0.40) | CHRNA1CHRNGCHRNB1CHRNB2SLC6A2 | |
| SCHEMBL3044469 | 0.82 | MAPT (0.39) | PKMALDH1A1RAB9ANPC1MAPT | |
| SCHEMBL3044470 | 0.82 | MAPT (0.39) | PKMALDH1A1RAB9ANPC1MAPT | |
| SCHEMBL3710894 | 0.81 | SIRT1 (0.39) | CHRNA1CHRNGCHRNB1CHRNB2SLC6A2 | |
| SCHEMBL3710891 | 0.81 | SIRT1 (0.39) | CHRNA1CHRNGCHRNB1CHRNB2SLC6A2 | |
| SCHEMBL3711785 | 0.80 | NPC1 (0.43) | CHRNA1CHRNGCHRNB1CHRNB2SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2358688-B1 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS INC (US) | 2014-03-12 | — | — | EP | disclosed |
| US-8440707-B2 | Antagonists of lysophosphatidic acid receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-20110301211-A1 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. | 2011-12-08 | — | — | US | disclosed |
| US-20110301142-A1 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. | 2011-12-08 | — | — | US | disclosed |
| US-8048902-B2 | Antagonists of lysophosphatidic acid receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2011-11-01 | — | — | US | disclosed |
| EP-2358688-A2 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | Amira Pharmaceuticals, Inc. (US) | 2011-08-24 | — | — | EP | disclosed |
| US-20110196005-A1 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC., (US) | 2011-08-11 | — | — | US | disclosed |
| WO-2010077883-A2 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
| WO-2010077882-A2 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
| US-20100152257-A1 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152257-A1 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | LPAR1, LPAR2, LPAR4 | CHRNA1 634/4885CHRNG 606/4885CHRNB1 678/4885 |
| US-20110196005-A1 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | LPAR1, LPAR2, LPAR4 | CHRNA1 634/4885CHRNG 606/4885CHRNB1 678/4885 |
| US-20110301211-A1 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | LPAR1, LPAR2, LPAR4 | CHRNA1 634/4885CHRNG 606/4885CHRNB1 678/4885 |
| US-20110301142-A1 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | LPAR1, LPAR2, LPAR4 | CHRNA1 634/4885CHRNG 606/4885CHRNB1 678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.